|
Characteristic
|
n
|
N
|
%
|
(95% CI)
|
|---|
|
Experienced diarrhoea in the past 2 weeks
|
|
No
|
1,077
|
1,242
|
86.7
|
(84.7–88.5)
|
|
Yes
|
165
|
1,242
|
13.3
|
(11.5–15.3)
|
|
ART status
|
|
No
|
90
|
1,242
|
7.3
|
(5.9–8.8)
|
|
Yes
|
1,152
|
1,242
|
92.8
|
(91.2–94.1)
|
|
Duration on ART in years
|
|
< 1
|
248
|
1,152
|
21.5
|
(19.2–24.0)
|
|
1–2
|
306
|
1,152
|
26.6
|
(24.1–29.2)
|
|
3–4
|
339
|
1,152
|
29.4
|
(26.9–32.1)
|
|
5–6
|
168
|
1,152
|
14.6
|
(12.7–16.7)
|
|
> 6
|
91
|
1,152
|
7.9
|
(6.5–9.6)
|
|
Median (IQR)
| |
1,152
|
3 (1.1–4.3)
| |
|
ART adherence in the past month
|
|
< 95%
|
83
|
1,139
|
7.3
|
(5.9–9.0)
|
|
≥ 95%
|
1,056
|
1,139
|
92.7
|
(91.0–94.1)
|
|
Missing
|
13
|
1,152
|
1.1
|
-
|
|
History of TB treatment
|
|
No
|
894
|
1,238
|
72.2
|
(69.6–74.6)
|
|
Yes
|
344
|
1,238
|
27.8
|
(25.4–30.4)
|
|
Missing
|
4
|
1,242
|
0.3
|
-
|
|
Current WHO stage
|
|
I/II
|
464
|
1,045
|
44.4
|
(41.4–47.4)
|
|
III/IV
|
581
|
1,045
|
55.6
|
(52.6–58.6)
|
|
Missing
|
197
|
1,242
|
15.9
|
-
|
|
Current CD4 cell counta
|
|
≤ 50
|
26
|
349
|
7.5
|
(5.1–10.7)
|
|
51–200
|
75
|
349
|
21.5
|
(17.5–26.1)
|
|
201–350
|
75
|
349
|
21.5
|
(17.5–26.1)
|
|
351–500
|
78
|
349
|
22.4
|
(18.3–27.0)
|
|
> 500
|
95
|
349
|
27.2
|
(22.8–32.2)
|
|
Missing
|
893
|
1,242
|
71.9
|
-
|
|
Median (IQR)
| |
349
|
348 (174–510)
| |
-
HIV Human Immunodeficiency Virus, ART antiretroviral therapy, IQR interquartile range, WHO World Health Organization
-
aCurrent CD4 cell count was taken as a CD4 cell count obtained with 6 months from date of data collection
